Lopinavir and Ritonavir
Active ingredient: Lopinavir, Ritonavir
In short: Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV1 infection in adults and pediatric patients 14 days and older. Limitations of Use:Genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir.
What is Lopinavir and Ritonavir used for?
Lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV1 infection in adults and pediatric patients 14 days and older.
Limitations of Use:Genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir .
Lopinavir and Ritonavir dosage
Lopinavir and ritonavir tablets may be taken with or without food. Swallow lopinavir and ritonavir tablets whole. Do not chew, break, or crush lopinavir and ritonavir tablets.
Give lopinavir and ritonavir in once daily or twice daily dosing regimen at dosages noted in Tables 1 and 2. Lopinavir and ritonavir once daily dosing regimen is not recommended in: •Adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V . •In combination with carbamazepine, phenobarbital, or phenytoin . •In combination with efavirenz, nevirapine, or nelfinavir . •In pediatric patients younger than 18 years of age .
In pregnant women [see Dosage and Administration (2.5), Use in Specific Populations (8.1) and Clinical Pharmacology (12.3)].
Table 1. Recommended Dosage in Adults -Lopinavir And Ritonavir Once Daily Regimen
Lopinavir And Ritonavir Dosage Form | Recommended Dosage
200 mg/50 mg Tablets | 800 mg/200 mg (4 tablets) once daily
Table 2. Recommended Dosage in Adults -Lopinavir And Ritonavir Twice Daily Regimen
Lopinavir And Ritonavir Dosage Form | Recommended Dosage
200 mg/50 mg Tablets | 400 mg/100 mg (2 tablets) twice daily
Increase the dose of lopinavir and ritonavir when administered in combination with efavirenz, nevirapine or nelfinavir. Table 3 outlines the dosage recommendations for twice daily dosing when lopinavir and ritonavir is taken in combination with these agents.
Table 3. Recommended Dosage in Adults -Lopinavir And Ritonavir Twice Daily Regimen in Combination with Efavirenz, Nevirapine, or Nelfinavir
Lopinavir And Ritonavir Dosage Form | Recommended Dosage
200 mg/50 mg Tablets and 100 mg/25 mg Tablets | 500 mg/125 mg (2 tablets of 200 mg/50 mg + 1 tablet of 100 mg/25 mg) twice daily
Lopinavir and ritonavir tablets are not recommended for once daily dosing in pediatric patients younger than 18 years of age. Lopinavir and ritonavir 100/25 mg tablets should be considered only in children who have reliably demonstrated the ability to swallow the intact tablet.
Pediatric Dosage Calculations
Calculate the appropriate dose of lopinavir and ritonavir for each individual pediatric patient based on body weight (kg) or body surface area (BSA) to avoid underdosing or exceeding the recommended adult dose. …
How to take Lopinavir and Ritonavir — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide)
General Administration Information :
•Advise patients to pay special attention to accurate administration of their dose to minimize the risk of accidental overdose or underdose of lopinavir and ritonavir. •Advise patients and caregivers that the oral solution should be administered using the calibrated dosing cup (supplied) or oral dosing syringe. •Advise caregivers to inform their healthcare provider if the child’s weight changes in order to make sure that the child’s lopinavir and ritonavir dose is adjusted as needed. •Inform patients and caregivers that lopinavir and ritonavir tablets may be taken with or without food. •Advise patients to remain under the care of a healthcare provider while using lopinavir and ritonavir and to take lopinavir and ritonavir in combination with other antiretroviral drugs as prescribed. •Advise patients not to alter the dose or discontinue therapy without consulting with their healthcare provider. If a dose of lopinavir and ritonavir is missed patients should take the dose as soon as possible and then return to their normal schedule. …
Warnings & precautions
Do not take this medicine if: Lopinavir and ritonaviris contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir.
Lopinavir and ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or lifethreatening reactions .
o Alpha 1-Adrenoreceptor Antagonist : alfuzosin
o Antianginal: ranolazine
o Antiarrhythmic: dronedarone
o Anti-gout: colchicine
o Antipsychotics: lurasidone, pimozide
o Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine
o GI Motility Agent: cisapride
o Hepatitis C direct acting antiviral: elbasvir/grazoprevir
o HMG-CoA Reductase Inhibitors: lovastatin, simvastatin
o Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide
o Non-opioid Analgesic(selective blocker of Nav1.8 sodium channels): suzetrigine
o PDE5 Inhibitor: sildenafil (Revatio®) when used for the treatment of pulmonary arterial hypertension
o Sedative/Hypnotics: triazolam, orally administered midazolam
Lopinavir and ritonavir is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance .
o Anticancer Agents: apalutamide
o Antimycobacterial: rifampin
o Herbal Products: St. John's Wort (hypericum perforatum)
Initiation of lopinavir and ritonavir, a CYP3A inhibitor, in patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving lopinavir and ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. …
Lopinavir and Ritonavir side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling.
QT Interval Prolongation, PR Interval Prolongation
Drug Interactions
Pancreatitis
Hepatotoxicity
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adverse Reactions in Adults The safety of lopinavir and ritonavir has been investigated in about 2,600 patients in Phase II-IV clinical trials, of which about 700 have received a dose of 800/200 mg (6 capsules or 4 tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, lopinavir and ritonavir was used in combination with efavirenz or nevirapine.
In clinical studies the incidence of diarrhea in patients treated with either lopinavir and ritonavir capsules or tablets was greater in those patients treated once daily than in those patients treated twice daily. Any grade of diarrhea was reported by at least half of patients taking once daily lopinavir and ritonavir capsules or tablets. At the time of treatment discontinuation, 4.2-6.3% of patients taking once daily lopinavir and ritonavir and 1.8-3.7% of those taking twice daily lopinavir and ritonavir reported ongoing diarrhea. …
Drug interactions
Lopinavir/ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (> 3-fold) when co-administered with lopinavir and ritonavir. Thus, co-administration of lopinavir and ritonavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 12.
Additionally, lopinavir and ritonavir induces glucuronidation.
Published data suggest that lopinavir is an inhibitor of OATP1B1.
These examples are a guide and not considered a comprehensive list of all possible drugs that may interact with lopinavir/ritonavir. The healthcare provider should consult appropriate references for comprehensive information.
Lopinavir/ritonavir is a CYP3A substrate; therefore, drugs that induce CYP3A may decrease lopinavir plasma concentrations and reduce lopinavir and ritonavir’s therapeutic effect. …
About this medicine
Lopinavir and ritonavir tablets are a co-formulation of lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 protease. As co-formulated in lopinavir and ritonavir, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
Lopinavir, USP is chemically designated as [1S-[1R*,(R*), 3R*, 4R*]]-N-[4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide. Its molecular formula is C37H48N4O5, and its molecular weight is 628.80. Lopinavir is a white to light tan powder. It is freely soluble in methanol and ethanol, soluble in isopropanol and practically insoluble in water. Lopinavir has the following structural formula:
Ritonavir, USP is chemically designated as 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, [5S-(5R*,8R*,10R*,11R*)]. Its molecular formula is C37H48N6O5S2, and its molecular weight is 720.95. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 115178c8-5ee2-4d96-820e-ea8264c1ac10. Read the full official label on DailyMed.